



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
April 17, 2024

Therapeutic Class	Drug Name	DURB Recommendation*
Macular Degeneration Agents		
	<i>Izervay (Intravitreal) Solution</i>	NP/PA on PADL
Biologic Immunomodulators		
	<i>Litfulo (Oral) Tablet</i>	NP/PA
Ophthalmics, Anti-Inflammatory/Immunomodulator		
	<i>Miebo (Ophthalmic) Solution</i>	NP/PA
Antidepressants, Other		
	<i>Zurzuvaе (Oral) Tablet</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'
Administered Drug List